The Blood Based Biomarker is majorly used to diagnose Alzheimer’s disease and track the progression of the disease
Blood Based Biomarker |
A Blood Based Biomarker may be used
as a screening tool for primary care clinics to determine whether a patient
needs an invasive procedure. As the population in the U.S. ages, this biomarker
could help primary care doctors determine which patients will require invasive
procedures. As there are over forty million people over 65 years old, this
population is projected to grow dramatically over the next few decades. For
instance, in May 2022, Germany partnered with India under its German Research
Foundation (DFG) to initiate International Research Training Group (IRTG)
programs, boosting research projects on blood based biomarkers and other scientific
breakthroughs. For this reason, these biomarkers may serve as a first-line
screening tool in a multistage approach.
The availability of a sensitive
blood-based biomarker for Alzheimer's disease is critical for validating new
therapies and improving care. This type of biomarker is easy to access,
relatively inexpensive, and non-invasive. A Blood Based Biomarker is one of the
most promising emerging technologies and is attracting tremendous research
interest. For Alzheimer's patients, this type of blood biomarker may help
doctors identify patients who have the disease early.
Although these Blood
Based Biomarker studies have not been cross-validated across
laboratories, their results suggest that they may have the highest impact as a
screening tool for Alzheimer's disease. The use of blood-based biomarkers in
primary care may allow doctors to detect patients early and provide appropriate
treatment. This is particularly important in low and middle-income countries,
where the disease is particularly prevalent. The use of panels of biomarkers is also promising,
as a combination of proteins may be more accurate than a single protein
candidate.
One such development is the use of a
blood based biomarker for Alzheimer's disease (AD). Although this field has
seen considerable progress in the past decade, it still has a long way to go.
In addition to advancing diagnostic testing, blood-based biomarkers may be able
to improve patient care and reduce the burden on healthcare systems. And the
benefits of early detection are huge. For
instance, patients with early-stage CRC have a better chance of surviving the
disease and a reduced risk of recurrence.
Comments
Post a Comment